W.L. Gore and Associates announced the FDA has granted a new indication for prevention of recurrent ischemic stroke for its patent foramen ovale closure device. The expanded approval of the device ...

- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...

It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...

The population of patients undergoing patent foramen ovale (PFO) closure in the US doesn’t match those of the clinical trials that formed the basis of the US Food and Drug Administration’s approval of ...

Patent foramen ovale (PFO) closure in conjunction with optimal medical therapy can reduce both the number of migraine days and the frequency of attacks compared with medicine alone, according to a new ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

PARIS – Holistick Medical SAS reported a $5 million round for development of the first generation of a light-activated implant for a patent foramen ovale (PFO). Truffle Capital provided the startup ...

Data indicate that there could be a link between cryptogenic thromboembolic events and patent foramen ovale (PFO). Although controversial, increasing numbers of patients are undergoing transcatheter ...